Advertisement

Tremorlytic activity of budipine in Parkinson’s disease

  • Sybille Spieker
  • S. Breit
  • T. Klockgether
  • J. Dichgans
Part of the Journal of Neural Transmission. Supplementa book series (NEURAL SUPPL, volume 56)

Summary

In order to objectively quantify the tremorlytic activity of budipine in Parkinson’s disease (PD) we performed longterm tremor recordings in a subset of patients enrolled in two clinical trials.

Eleven PD patients with marked tremor participating in an open-label study underwent longterm recording before and during medication. Nine patients completed the study. Tremor occurrence was reduced from 52 ± 18.6% to 34.7 ± 19.3% (p < 0.05); tremor intensity decreased from 15.3 ± 4.8 (SNR)to 11.3 ± 4.8 (p < 0.01). UPDRS tremor subscores were also significantly improved.

Fourteen patients who enrolled in a multicenter, double-blind, placebo-controlled study underwent longterm tremor analysis in addition to the Columbia University Rating Scale (CURS). Tremor occurrence was improved in the budipine group (n = 7) from 24.7 ± 15.5% to 14.8 ± 14.5% (p < 0.05). Tremor intensity decreased from 9.1 ± 2.5 (SNR) to 7.2 ± 1.6. However, the latter result was statistically not significant, probably due to the small patient number. In the placebo-group (n = 7) there was no reduction of tremor occurrence or of tremor intensity. The CURS sum score was improved from 5.7 to 3.0 in the budipine group, whereas there was only a smaller improvement in the placebo group (from 7.1 to 5.5).

These data suggest that budipine is an effective tremorlytic agent in PD, which may by used as an alternative to anticholinergics.

Keywords

Postural Tremor Levodopa Equivalance Dose Tremor Intensity Study Adverse Effect Tremor Recording 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bacher M, Scholz E, Diener HC (1989) 24 hour continuous tremor quantification based on EMG recording. Electroencephalogr Clin Neurophysiol 72: 176–183PubMedCrossRefGoogle Scholar
  2. Duvoisin RC (1971) The evaluation of extrapyramidal disease. In: Ajuriaguerra J, Gauthier G (eds) Monoamines noyaux gris centraux et syndrome de Parkinson. Georg & Cie, Genf, pp 313–325Google Scholar
  3. Fahn S, Tolosa E, Marin C (1988) Clinical rating scale for tremor. In: Jankovic J, Tolosa E (eds) Parkinson’s disease and movement disorders. Urban & Schwarzenberg, Baltimore, pp 225–234Google Scholar
  4. Iizuka J (1985) Controlled single-blind trial of budipine, L-dopa, and amantadine in 102 patients with Parkinson’s disease. In: Gerstenbrand WPF, Stern G (eds) Clinical experiences with Budipine in Parkinson therapy. Springer, Berlin Heidelberg New York Tokyo, pp 129–139CrossRefGoogle Scholar
  5. Ketz E (1985) Open clinical trial of budipine in 25 tremor dominant parkinsonian patients. In: Gerstenbrand F, Poewe W, Stern G (eds) Clinical experiences with budipine in Parkinson therapy. Springer, Berlin Heidelberg New York Tokyo, pp 140–141CrossRefGoogle Scholar
  6. Kirshner B, Guyatt G (1985) A methodological framework for assessing health indices. J Chronic Dis 38: 27–36PubMedCrossRefGoogle Scholar
  7. Spieker S, Jentgens C, Boose A, Dichgans J (1995) Reliability, specificity and sensitivity of long-term tremor recordings. Electroencephalogr Clin Neurophysiol 97: 326–331PubMedCrossRefGoogle Scholar
  8. Spieker S, Ströle V, Sailer A, Boose A, Dichgans J (1997) Validity of longterm EMG in the quantification of tremor. Mov Disord 12: 985–991PubMedCrossRefGoogle Scholar
  9. Ulm G (1985) Effect of Budipine on Parkinsonian tremor resistant to other Parkinsonian mediation. In: Gerstenbrand WPF, Stern G (eds) Clinical experiences with Budipine in Parkinson therapy. Springer, Berlin Heidelberg New York Tokyo, pp 142–151CrossRefGoogle Scholar
  10. Webster DD (1968) Critical analysis of the disability in Parkinson’s disease. Mod Treat 5: 257–282PubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 1999

Authors and Affiliations

  • Sybille Spieker
    • 1
  • S. Breit
    • 1
  • T. Klockgether
    • 1
  • J. Dichgans
    • 1
  1. 1.Department of NeurologyUniversity of TübingenTübingenFederal Republic of Germany

Personalised recommendations